ClinicalTrials.gg

Program

ganaplacide

A development code. Also written as “KLU156”.

In Novartis’s pipeline, Non-artemisinin plasmodium falciparum inhibitor. Its studies are mostly in Malaria, Falciparum, led by Novartis.

Furthest: phase 3, since Apr 24, 20234 company-led studies, 2 open or runningNext primary completion: Feb 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis42 open or runningphase 3since Apr 24, 2023Feb 17, 2023Feb 4, 2027phase 2 · NCT07811908
  • Named in Novartis’s own pipeline as KLU156 (Ganaplacide + lumefantrine), phase 4, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2023First study: phase 2 study in MalariaFirst studyNCT05750628 · 327 planned · Burkina Faso, Côte d’Ivoire, Gabon and more
  2. Apr 24, 2023Phase 3 study in MalariaNCT05842954 · 1,720 enrolled · Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo and more
  3. Nov 14, 2025Phase 2 study in Malaria, FalciparumNCT07235033 · 60 enrolled · Côte d’Ivoire, Gabon, Kenya
  4. Sep 4, 2026Phase 2 study in Malaria, FalciparumNCT07811908 · 120 planned · Burkina Faso, Côte d’Ivoire, Gabon and more

Ahead

  1. Feb 4, 2027Primary completion: phase 2 study in Malaria, FalciparumNCT07811908

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Non-artemisinin plasmodium falciparum inhibitor”the company's pipeline, read by Claude · source

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07811908Malaria, Falciparum · Burkina Faso, Côte d’Ivoire, Gabon and more2RecruitingFeb 4, 2027120
NCT07235033Malaria, Falciparum · Côte d’Ivoire, Gabon, Kenya2CompletedMar 5, 202560
NCT05842954Malaria · Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo and more3CompletedJun 27, 20251,720
NCT05750628Malaria · Burkina Faso, Côte d’Ivoire, Gabon and more2RecruitingJun 9, 2026327

How it is read

Names in the registry

  • “KLU156”, 4 entries

Codes read as this program: KLU156.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ganaplacide (Novartis): development program | ClinicalTrials.gg